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Abstract
Objective
To investigate the relationship between cognitive reserve (CR) and clinical progression across
the Alzheimer disease (AD) spectrum.
Methods
We selected 839 β-amyloid (Aβ)–positive participants with normal cognition (NC, n = 175),
mild cognitive impairment (MCI, n = 437), or AD dementia (n = 227) from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI). CR was quantiﬁed using standardized residuals (W
scores) from a (covariate-adjusted) linear regression with global cognition (13-item Alz-
heimer’s Disease Assessment Scale–cognitive subscale) as an independent variable of interest,
and either gray matter volumes or white matter hyperintensity volume as dependent variables.
These W scores, reﬂecting whether an individual’s degree of cerebral damage is lower or higher
than clinically expected, were tested as predictors of diagnostic conversion (i.e., NC to MCI/
AD dementia, or MCI to AD dementia) and longitudinal changes in memory (ADNI-MEM)
and executive functions (ADNI-EF).
Results
Themedian follow-up period was 24 months (interquartile range 6–42). Corrected for age, sex,
APOE4 status, and baseline cerebral damage, higher gray matter volume-based W scores
(i.e., greater CR) were associated with a lower diagnostic conversion risk (hazard ratio [HR]
0.22, p < 0.001) and slower decline in memory (β = 0.48, p < 0.001) and executive function (β =
0.67, p < 0.001). Stratiﬁed by disease stage, we found similar results for NC (diagnostic
conversion: HR 0.30, p = 0.038; ADNI-MEM: β = 0.52, p = 0.028; ADNI-EF: β = 0.42, p =
0.077) and MCI (diagnostic conversion: HR 0.21, p < 0.001; ADNI-MEM: β = 0.43, p = 0.003;
ADNI-EF: β = 0.59, p < 0.001), but opposite ﬁndings (i.e., more rapid decline) for AD dementia
(ADNI-MEM: β = −0.91, p = 0.002; ADNI-EF: β = −0.77, p = 0.081).
Conclusions
Among Aβ-positive individuals, greater CR related to attenuated clinical progression in pre-
dementia stages of AD, but accelerated cognitive decline after the onset of dementia.
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A major limitation in the care and management of Alz-
heimer disease (AD) is the inability to provide patients
with an accurate prognosis. Cognitive reserve (CR), the
brain’s capability to preserve cognition despite underlying
cerebral damage,1 may be a key determinant of clinical
progression. Previous studies have demonstrated a para-
dox: while CR is associated with a delayed symptom
onset,2–7 it is related to accelerated cognitive decline in
advanced AD stages.8–15 Other studies, however, found no
longitudinal CR associations.16–19
These inconclusive results have several explanations. First,
various studies used lifestyle proxies to operationalize CR
(e.g., education, occupation, or physical activity),20 but there
is no consensus about the validity of these indirect
measures.3,21,22 Second, presence of AD was often established
through clinical evaluation without consideration of AD bio-
markers, likely resulting in samples confounded with non-AD
participants. Third, few studies comprehensively investigated
the relationship between CR and clinical progression across
the entire AD spectrum, thus hampering a direct comparison
between disease stages.
We optimized the examination of CR in relation to AD-
related clinical progression by (1) using a (more direct)
neuroimaging measure of CR, based on cognitive and struc-
tural brain measures,23 (2) selecting β-amyloid (Aβ)–positive
individuals only, and (3) including participants across the
entire AD spectrum (i.e., normal cognition [NC], mild cog-
nitive impairment [MCI], and AD dementia). We hypothe-
sized that greater CR related to attenuated diagnostic
conversion risk and slower cognitive decline in early disease
stages, but exacerbated clinical progression among clinically
advanced participants.
Methods
Participants
All participants were recruited within the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) and enrolled at sites in the
United States and Canada across 3 funding cycles (ADNI-1,
ADNI-GO, and ADNI-2).24 They were aged between 55 and
91 years at baseline, English or Spanish speakers, non-
depressed, and classiﬁed as NC, MCI, or AD dementia.
Follow-up visits were scheduled every 6 months in the ﬁrst 2
years, and annually thereafter. Cognitive status was evaluated
with the Clinical Dementia Rating scale, Mini-Mental State
Examination (MMSE), and Wechsler Memory Scale Logical
Memory II. Cognitive assessments, physical examinations,
and MRI scans were considered in determining diagnostic
status. We selected all NC, MCI, and AD dementia partic-
ipants with positive AD biomarkers (11C–Pittsburgh com-
pound B or 18F-ﬂorbetapir PET25,26 if available, or CSF
Aβ42
27), structural MRI, and neuropsychological data at
baseline. We excluded individuals with MRI segmentation
failures (n = 2), development of non-AD dementia or other
neurologic disorders during follow-up (n = 5), and >6months
between baseline MRI and neuropsychological assessment (n
= 2). Our ﬁnal Aβ-positive sample (n = 839) included 175
NC, 437 MCI, and 227 AD dementia participants (ﬁgure 1).
Follow-up data were available for 96% of the dataset. The
remaining 4% was included to improve estimation of baseline
eﬀects in statistical models.
Standard protocol approvals, registrations,
and patient consents
Written informed consent was obtained for all participants,
and study procedures were approved by the institutional re-
view board at each of the participating centers. ADNI is listed
in the ClinicalTrials.gov registry (ADNI-1: NCT00106899;
ADNI-GO: NCT01078636; ADNI-2: NCT0123197).
MRI acquisition and preprocessing
Structural MRI scans were acquired on 1.5T and 3T scanners
from GE Healthcare (Cleveland, OH), Philips Medical Sys-
tems (Best, the Netherlands), and Siemens Medical Solutions
(Malvern, PA) (adni.loni.usc.edu/methods/mri-analysis/
mri-acquisition/).28 We downloaded T1 scans preprocessed
with gradwarping, B1 correction, or N3 scaling for the present
analyses. We further preprocessed these images using SPM12,
before extracting gray matter (GM) volumes for all 839 par-
ticipants. We computed intracranial volume (ICV) as the sum
of GM, white matter, and CSF. White matter hyperintensity
(WMH) volumes were segmented from proton density and
T2 images (ADNI-1) or 2D–ﬂuid-attenuated inversion
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recovery (ADNI-GO/2) by the ADNI core laboratory using
automated techniques29,30 and downloaded from the website
for 796/839 participants. We log-transformed the WMH
volumes to account for non-normality.
Structural brain measures
To quantify cerebral damage, we extracted GM volume on
a whole-brain level and from bilateral temporoparietal and
hippocampal masks (based on the Automated Anatomical
Labeling atlas; ﬁgure e-1, doi.org/10.5061/dryad.cb0qk1g)
31,32 and obtained global WMH volumes. As described below,
these measures were included as dependent variables in
models to create W scores, our operational measure of CR.
Furthermore, GM and WMH volumes served as individual
predictors of clinical progression in statistical models. For this
purpose, we corrected for premorbid brain size by regressing
out the eﬀect of ICV, and used standardized GM or WMH
volume residuals for further statistical analysis.
Neuropsychological assessment
Cognitive measures in our study were 13-item Alzheimer’s
Disease Assessment Scale–cognitive subscale (ADAS-Cog),
ADNI-MEM, and ADNI-EF. ADAS-Cog 13 is a global cog-
nitive screening test that includes 13 subtests for memory,
language, praxis, attention, visuoconstruction, and orienta-
tion.33 ADNI-MEM is a composite score based on the Rey
Auditory Verbal Learning task, word list learning and recog-
nition tasks from ADAS-Cog, recall from Logical Memory I of
the Wechsler Memory Test–Revised, and the 3-word recall
item from the MMSE.34 ADNI-EF consists of Category Flu-
ency (i.e., animals and vegetables), Trail-Making Test part A
and B, Digit Span Backwards, Wechsler Adult Intelligence
Scale–Revised Digit–Symbol Substitution, and 5 Clock
Drawing items.35 In statistical analyses, we multiplied ADNI-
MEM and ADNI-EF scores by 100 to facilitate the pre-
sentation of results.
Calculation of W scores
Our neuroimaging approach takes the general relationship
between cognition and cerebral damage as a starting point,
and uses this information to estimate an individual’s expected
degree of cerebral damage based on cognitive performance.
This expected value is then compared with an individual’s
actual degree of cerebral damage, and the diﬀerence is referred
to as a W score, our operational measure of CR.23,36,37 Ce-
rebral damage was quantiﬁed using 4 measures: GM volume,
either whole-brain (1) or within speciﬁc temporoparietal (2)
or hippocampal masks (3), and global WMH volume (4).
These measures were used as dependent variables in separate
linear regressions that further included global cognitive per-
formance (ADAS-Cog 13) as an independent variable of in-
terest, and age, sex, ICV, and scanner ﬁeld strength as
covariates. Education was not added as a covariate, since this is
one of the contributing factors of CR (i.e., our concept of
interest). We obtained standardized residuals from these
regressions and multiplied them by −1 to derive W scores
(this multiplication was omitted for WMH volumes, as higher
volumes already reﬂect greater cerebral damage). Speciﬁcally,
we used the following formula: W score (CR) = −1 × (ob-
served cerebral damage − predicted cerebral damage/SD).
Higher W scores reﬂect greater CR, because they indicate that
Figure 1 Selection procedure of the sample
Aβ = β-amyloid; AD = Alzheimer disease;
ADNI = Alzheimer’s Disease Neuro-
imaging Initiative; MCI = mild cognitive
impairment; NC = normal cognition; NPA
= neuropsychological assessment.
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a relatively high degree of cerebral damage is tolerated at
a given level of cognitive function. We obtained 4 diﬀerent W
scores for further analysis (i.e., 3 GM-based W scores, 1
WMH-based W score).
Data availability
All imaging, demographics, and neuropsychological data used
in this article are publicly available and were downloaded from
the ADNI website (adni.loni.usc.edu). Upon request, we will
provide a list of ADNI participant identiﬁcations for replica-
tion purposes.
Statistical analysis
Participant characteristics
Statistical analyses were performed in SPSS 22 (Chicago, IL).
Analysis of variance (ANOVA), χ2, and Kruskal-Wallis tests
were used to compare disease stages by demographic variables,
follow-up time, cognitive performance, ICV, andW scores. We
used a multiple imputation procedure for the 0.3% of cognitive
measures missing at baseline. This procedure was performed
using the fully conditional speciﬁcation method in SPSS, which
is an iterativeMarkov ChainMonte Carlo approach suitable for
arbitrary patterns of missing data. We imputed 15 data sets and
included demographic, clinical, and neuropsychological varia-
bles and ICV as predictors in the model.
Relationships among W scores, structural
brain measures, and education
First, we correlated W scores with the (ICV-adjusted) struc-
tural brain measures from which they were calculated (i.e., GM
or WMH volume). We expected that these variables were in-
terrelated because the higher the degree of cerebral damage, the
greater the potential manifestation of CR. Moreover, as
mathematically explained elsewhere,38 residuals from linear
regressions are inherently correlated with their dependent
variables. Such a correlation would suggest that the relationship
between W scores and clinical progression cannot be correctly
interpreted without taking into account in the presence of ce-
rebral damage, and thus we evaluated whether these structural
measures could be included as covariates in subsequent sta-
tistical models, without violating the assumptions of multi-
collinearity. We considered a correlation r <0.8 between W
scores and their related structural brain measure39 and a vari-
ance inﬂation factor (VIF) <5 for these variables in combina-
tion with other covariates (age, sex, APOE4 status)40 an
acceptable level of multicollinearity. Furthermore, we de-
termined the relationship of W scores and structural brain
measures with education. As education is a well-known lifestyle
proxy of CR, W scores should show a (positive) relationship
with education, while this is not necessarily the case for the
structural brain measures. We therefore grouped participants
with lower (≤14 years, n = 264), intermediate (15–17 years, n =
286), and higher education (>18 years, n = 289) and performed
ANOVAs to examine diﬀerences among these groups in W
scores (ICV-adjusted) and GM and WMH volumes.
W scores and diagnostic conversion
We performed Cox regressions among predementia partic-
ipants (NC, n = 175; MCI, n = 437) to study relationships
between (continuous) W scores and diagnostic conversion
(i.e., change in baseline diagnosis from NC to MCI/AD de-
mentia, or fromMCI to AD dementia). Diagnostic changes to
a less advanced disease stage (e.g., MCI to NC, which spo-
radically occurred in the sample) was not considered a con-
version. We ran 4 models for each W score, and included the
related structural measure (i.e., ICV-adjusted whole-brain,
temporoparietal, or hippocampal GM volume or WMH vol-
ume), age, sex, and APOE4 status as covariates. These anal-
yses were also stratiﬁed for MCI and NC. We used 95%
conﬁdence intervals (CIs) to compare W score eﬀects be-
tween disease stages; diﬀerences were considered signiﬁcant
when the eﬀect size for one group fell outside of the CI of the
other group.41
W scores and cognitive decline
To examine clinical progression in more psychometric detail,
we performed linear mixed models with memory (ADNI-
MEM) and executive functioning (ADNI-EF) as outcome
variables and (continuous) W score, time (i.e., months), and
W score × time as predictors. The interaction term was the
eﬀect of interest, as it reﬂected whether CR moderated the
relationship between time and cognitive performance. Our
models contained random intercepts and slopes. Note that, in
contrast to the Cox regressions, the AD dementia group (n =
227) was now also included for analysis. Again, we ran sep-
arate models for each W score in the total group and stratiﬁed
by disease stage, while correcting for structural measures
(ICV-adjusted GM or WMH volume, and their interaction
with time) as well as age, sex, and APOE4 status.
In secondary analyses, we repeated the main linear mixed
models, but only included time points that were collected
until the (ﬁrst) date of diagnostic conversion. To illustrate the
relevance of this analysis, consider a participant with MCI at
baseline, a diagnostic conversion to AD dementia at 48
months, and a total follow-up of 108 months. In stratiﬁed
analyses, this participant would be classiﬁed into the MCI
group, although 56% of the data actually concern clinical
progression during the AD dementia stage. Constraining the
linear mixed models to exclusively consider data from the
initial diagnosis leads to results that are completely non-
overlapping with respect to disease stage (and thus more
easily interpretable).
Comparison with other models of
clinical progression
If our W scores were related to clinical progression, we would
assume that this is an eﬀect of CR. However, an alternative
explanation would be that W scores are a derivative measure
of cerebral damage, which presumably also relates to clinical
progression. Although we partly accounted for this by in-
cluding structural brainmeasures as covariates in the statistical
models, we explicitly aimed to investigate whether W scores
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added explanatory value to the prediction of clinical pro-
gression. We therefore compared our main models of clinical
progression (which included both structural brain measures
and W scores) to models in which W scores were not in-
cluded. We used the Akaike Information Criterion (AIC)42 to
evaluate which of the 2 models showed a better ﬁt to the data.
AIC assesses the model ﬁt while also penalizing the number of
predictors, thus favoring models with the optimal trade-oﬀ
between parsimony and goodness-of-ﬁt. A lower AIC value
indicates a better model. We also assessed whether including
W scores in models with a cognitive measure (ADAS-Cog 13)
resulted in signiﬁcant AIC improvements.
Sensitivity analyses
We performed additional analyses to ensure that our main
ﬁndings were robust to diﬀerent methodologic decisions. We
recalculated theW scores in 2 ways: (1) we allowed a nonlinear
relationship between cognition and cerebral damage by adding
a quadratic term (i.e., ADAS-Cog 132), as the CR theory
describes a curve that reﬂects a relationship between cerebral
damage and clinical symptoms that is initially ﬂat and changes
exponentially; (2) we created W scores based on ADNI-MEM
and ADNI-EF as cognitive measures and instead used ADAS-
Cog 13 as an outcome measure of cognitive decline. These
recalculated W scores were replaced with the original W scores
in the Cox regressions and linear mixed models, and we
assessed whether this replacement led to relevant changes.
Results
Participant characteristics
Table 1 provides an overview of our Aβ-positive sample
(mean age 73.9 years; median education 16 years). De-
mographic characteristics were similar across disease stages,
except that the proportion of APOE4 positivity was higher
among more advanced disease stages (NC: 45.7%, MCI:
63.2%, AD dementia: 73.6%),43 and the NC group included
more female participants (58.3%) relative to MCI and AD
dementia groups (42.3% and 43.6%, respectively). NC par-
ticipants also had a lower ICV (1,482.1 ± 145.1 cm3) com-
pared to MCI participants (1,519.3 ± 157.6 cm3), and their
GM-based hippocampal W scores (−0.27 ± 0.91) were lower
than in MCI and AD dementia participants (0.07 ± 1.01, 06 ±
1.00, respectively). The other W scores were comparable
across disease stages. On all cognitive measures, there were
signiﬁcant baseline diﬀerences between disease stages in the
expected direction (i.e., AD dementia < MCI < NC). Simi-
larly, CSF biomarkers were more abnormal with increasing
clinical severity (i.e., lower CSF Aβ and higher CSF p-tau and
t-tau). The median follow-up was 24 months (interquartile
range [IQR] 6–42) in the total sample, with a shorter duration
in the AD dementia group (median 12 months, IQR 6–18)
compared to the other 2 groups (median 36 months, IQR
24–48). Diagnostic conversion toMCI occurred in 21% of the
NC sample, and 32% of all predementia cases showed (ad-
ditional) diagnostic conversion to AD dementia.
Relationships among W scores, structural
brain measures, and education
As expected, each W score showed a signiﬁcant correlation
with the structural brain measure from which it was derived
(table e-1, doi.org/10.5061/dryad.cb0qk1g). Assumptions of
multicollinearity were not violated (i.e., r < 0.8 and VIF <5 in
all cases), thus we included the structural brain measures as
covariates in the statistical models assessing the eﬀect of W
scores on clinical progression. ANOVA revealed signiﬁcant
diﬀerences between education groups for GM-based whole-
brain (p = 0.043) and temporoparietal W scores (p = 0.047),
such that highly educated participants showed higher W
scores (i.e., greater CR) than those with lower education. The
other 2 W scores and all structural brain measures did not
show relationships with education (table 2). Since the asso-
ciation with education is an important validation step for the
use of W scores as an operational measure of CR, we will only
discuss results from the GM-based whole-brain and tempor-
oparietal W scores here. However, all main statistical analyses
were also performed in the GM-based hippocampal and
WMH-based W scores (tables e-2–e-4, doi.org/10.5061/
dryad.cb0qk1g). For simplicity, we will refer to “whole-brain/
temporoparietal W scores” in the remaining Results sections,
thus omitting the term “GM-based.”
W scores and diagnostic conversion
Cox regressions in predementia participants (n = 612) showed
a negative association between whole-brain W scores and di-
agnostic conversion risk (222 conversions; whole brain: hazard
ratio [HR] 0.22, p < 0.001; temporoparietal: HR 0.25, p <
0.001), indicating that greater CR related to a lower risk.
Stratiﬁed by disease stage, this ﬁnding was present in both the
NC group (38 conversions; whole brain: HR 0.30, p = 0.038;
temporoparietal: HR 0.30, p = 0.021) and the MCI group (184
conversions; whole brain: HR 0.21, p < 0.001; temporoparietal:
HR 0.25, p < 0.001). An overview of allW scoremodels and the
eﬀect of each individual predictor on diagnostic conversion is
available (table e-2; doi.org/10.5061/dryad.cb0qk1g).
W scores and cognitive decline
Linear mixed models in the total sample (n = 839) showed
that higher whole-brain W scores were related to better
baseline performance on ADNI-MEM (β = 121.19, p < 0.001)
and ADNI-EF (β = 86.78, p < 0.001). Furthermore, these
scores declined over time (ADNI-MEM: β = −1.35, p < 0.001;
ADNI-EF: β = −1.28, p < 0.001). Importantly, this relation-
ship was moderated by CR, such that participants with higher
W scores (i.e., greater CR) showed an attenuated decline in
ADNI-MEM (β = 0.48, p < 0.001) and ADNI-EF (β = 0.67, p
< 0.001). When stratifying by disease stage, these interaction
eﬀects for ADNI-MEM remained similar among NC (β =
0.52, p = 0.028) and MCI participants (β = 0.43, p = 0.003),
but were inverted in the AD dementia group (β = −0.91, p =
0.002). A similar pattern was observed for ADNI-EF (NC:
β = 0.42, p = 0.077; MCI: β = 0.59, p < 0.001; AD dementia:
β = −0.77, p = 0.081), although these eﬀects were slightly
weaker and mostly nonsigniﬁcant. The results for AD dementia
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participants were signiﬁcantly diﬀerent from the other 2 groups
(ﬁgure 2). Results for temporoparietal W scores were highly
comparable (table 3). An overview of all W score models and the
eﬀect of each individual predictor on cognitive decline is available
(tables e-3 and e-4, doi.org/10.5061/dryad.cb0qk1g). Finally,
repeating our main analyses using only within-disease stage time
points yielded results in the same direction for both whole-brain
and temporoparietal W scores. The eﬀects for NC participants
were no longer signiﬁcant (table e-5, doi.org/10.5061/dryad.
cb0qk1g).
Table 1 Characteristics of the total sample and according to disease stages
Total NC MCI AD dementia p Value
N 839 175 437 227 —
Demographics
Age, y 73.9 (7.2) 74.6 (5.9) 73.3 (7.1) 74.3 (8.1) 0.086
Sex, % female 46.0 58.3 42.3 43.6 0.001i,j
APOE4, % positive 62.3 45.7 63.2 73.6 <0.001i–k
Education, ya 16.0 (14.0–18.0) 16.0 (14.0–18.0) 16.0 (14.0–18.0) 16.0 (13.5–18.5) 0.051
Cognition
MMSE 26.7 (2.8) 29.1 (1.1) 27.5 (1.8) 23.2 (2.0) <0.001i–k
ADAS-Cog 13 19.4 (10.2) 9.5 (4.3) 17.5 (6.8) 30.7 (8.3) <0.001i–k
ADNI-MEM −0.0 (0.9) 1.0 (0.6) 0.1 (0.7) −0.9 (0.6) <0.001i–k
ADNI-EF −0.1 (1.0) 0.6 (0.7) 0.1 (0.8) −0.9 (0.8) <0.001i–k
Brain measures
CSF Aβ42, ng/L
b 140.7 (29.4) 153.9 (31.6) 141.1 (29.6) 129.6 (21.9) <0.001i–k
CSF p-tau, ng/Lb 47.0 (25.9) 39.3 (22.7) 46.8 (23.7) 53.7 (30.5) <0.001i–k
CSF t-tau, ng/Lb 107.3 (58.5) 76.9 (39.0) 107.7 (58.3) 131.2 (61.1) <0.001i–k
ICV, cm3 1,508.6 (160.0) 1,482.1 (145.1) 1,519.3 (157.6) 1,508.4 (173.3) 0.034i
W score (whole-brain)c 0.0 (1.0) 0.0 (1.0) −0.0 (1.0) 0.0 (1.0) 0.807
W score (temporoparietal)d 0.0 (1.0) −0.0 (0.9) −0.0 (1.0) 0.1 (1.0) 0.475
W score (hippocampal)e 0.0 (1.0) −0.3 (0.9) 0.1 (1.0) 0.1 (1.0) <0.001i,j
W score (WMH)f 0.0 (1.0) 0.0 (1.0) 0.0 (1.0) −0.0 (1.1) 0.893
Clinical progression
Follow-up, moa 24.0 (6.0–42.0) 36.0 (24.0–48.0) 36.0 (24.0–48.0) 12.0 (6.0–18.0) <0.001j,k
Conversion to MCI, n (%)g 37 (4.4) 37 (21.1) — — —
Conversion to AD, n (%)h 195 (23.2) 11 (6.3) 184 (42.1) — —
Abbreviations: AD = Alzheimer disease; ADAS-Cog = Alzheimer’s Disease Assessment Scale–cognitive subscale; ADNI = Alzheimer’s Disease Neuroimaging
Initiative; ADNI-EF = standardized composite score based on a clock drawing task, animal and vegetable category fluency, the Trail-making task, Digit Span
Backwards from theWechslerMemory Scale–Revised, and the digit–symbol substitution task from theWechsler Adult Intelligence Test–Revised; ADNI-MEM=
standardized composite score based on the Alzheimer’s Disease Assessment Scale–cognitive subscale word list learning task, the Rey Auditory Verbal
Learning Test, Logical Memory from the Wechsler Memory Scale–Revised, and the Mini-Mental State Examination recall task; GM = gray matter; ICV =
intracranial volume, inmL; IQR = interquartile range;MCI =mild cognitive impairment;MMSE=Mini-Mental State Examination; NC= normal cognition;WMH=
white matter hyperintensities.
Data are presented as mean (SD) unless indicated otherwise.
a Data expressed as median (IQR).
b These data were measured in CSF (available for 789 [β-amyloid and p-tau] and 776 [t-tau]/839 cases).
c W score based on GM volume in a whole-brain mask.
d W score based on GM volume in a temporoparietal mask.
e W score based on GM volume in a hippocampal mask.
f W score based on WMH volume (available for 796/839 cases).
g This number includes 10 NC participants who additionally converted to AD at a later time point.
h This number includes 1 NC participant from whom an earlier conversion to MCI was not reported.
i Significant difference between NC vs MCI.
j Significant difference between NC vs AD dementia.
k Significant difference between MCI vs AD dementia.50
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Comparison with other models of
clinical progression
We evaluated the added explanatory value of W scores in
models of clinical progression by assessing diﬀerences be-
tween models with W scores and without W scores. The
models with GM volume that included W scores showed the
lowest AIC values (i.e., better model ﬁt; Cox regression: D =
−101.08; linear mixed models [ADNI-MEM, ADNI-EF]: D =
−889.72, D = −345.74). In models with ADAS-Cog 13 (in-
stead of GM volume) as the main predictor of clinical pro-
gression, adding W scores also yielded a lower AIC (Cox
regression: D = −14.20; linear mixed models [ADNI-MEM,
ADNI-EF]: D = −17.96, D = −90.78). We found similar
results for temporoparietal W scores (table 4).
Sensitivity analyses
W scores that were created from a model allowing a nonlinear
relationship between cognition andwhole-brainGMvolume had
similar associations with clinical progression (Cox regression:
HR 0.21, p < 0.001; linearmixedmodels, ADNI-MEM: β = 0.41,
p< 0.001; ADNI-EF: β = 0.62, p< 0.001).Whole-brainW scores
calculated based on ADNI-MEM and ADNI-EF as cognitive
measures (instead of ADAS-Cog 13) showed results in the same
direction for diagnostic conversion (HR 0.25, p < 0.001) and
longitudinal changes in ADAS-Cog 13 (β = −0.11, p< 0.001; this
eﬀect is reversed as higher scores reﬂect worse performance).
This was also found for temporoparietal W scores (tables e-6–e-
8, doi.org/10.5061/dryad.cb0qk1g). Likewise, the results from
stratiﬁed analyses did not show relevant changes as a function of
whole-brain and temporoparietal W score adjustments, except
that we no longer found an exacerbating eﬀect on clinical pro-
gression in AD dementia. The sensitivity analyses yielded largely
similar results as observed in the primary analyses, although
ﬁndings among theADdementia groupwere not fully replicated.
Discussion
In the present study we investigated how CR, deﬁned as the
degree to which an individual’s observed cerebral damage was
higher or lower than predicted from cognitive performance,
aﬀected clinical progression in AD. In an Aβ-positive sample
of participants in diﬀerent stages across the entire disease
spectrum (i.e., NC, MCI, and AD dementia), we found that
CR inﬂuenced diagnostic conversion risk and the rate of
cognitive decline. Importantly, these eﬀects were not uniform
across disease stages. While CR was associated with attenu-
ated clinical progression in NC and MCI participants, it re-
lated to exacerbated cognitive decline among individuals with
AD dementia. A possible explanation for these ﬁndings is that
every individual—regardless of CR—reaches the end stage of
AD at roughly the same time or level of cerebral damage, and
thus a delayed symptom onset or slower initial decline is
inherently counterbalanced by a faster progression towards
this end point.1 Understanding these complex longitudinal
associations of CR with clinical progression may improve the
accuracy of individualized prognoses for patients with AD.
Although previous literature in the context of AD has not
consistently shown a relationship between CR and clinical
progression,16–19 there are several studies within early
stages of AD that also reported CR-related attenuated
decline or delay in symptom onset. These studies deﬁned
CR by educational level,4,5,7 composite scores,2,6 or a “re-
sidual approach”–based measure (comparable to our W
score method).3 Likewise, multiple studies have previously
demonstrated that after the (delayed) onset of clinical
symptoms, patients with higher CR show a steeper func-
tional decline. This was found for symptomatic individuals
with higher education,8,10,12,15 occupation,8,11 premorbid
Table 2 Mean W scores and other predictors of clinical progression across 3 education groups
Low education
(≤14 years)
Intermediate education
(15–17 years)
High education
(≥18 years) p Value
W score (whole brain)a −0.10 (1.01) −0.02 (0.96) 0.11 (1.01) 0.043e
W score (temporoparietal)b −0.09 (1.03) −0.03 (0.95) 0.11 (1.00) 0.047e
W score (hippocampal)c −0.07 (1.01) −0.03 (1.00) 0.10 (0.98) 0.123
W score (WMH)d 0.06 (1.03) −0.07 (1.03) 0.01 (0.92) 0.323
GM volume (whole brain) −0.04 (0.99) 0.02 (0.99) 0.02 (1.02) 0.764
GM volume (temporoparietal) −0.05 (1.01) 0.02 (0.99) 0.02 (1.00) 0.671
GM volume (hippocampal) −0.08 (0.94) 0.02 (1.01) 0.05 (1.04) 0.265
WMH 0.04 (1.06) −0.01 (0.97) −0.03 (0.97) 0.769
Abbreviations: GM = gray matter; WMH = white matter hyperintensities.
Data are based on analyses of variance comparing 3 education groups, and are presented as mean (SD).
a W score based on GM volume in a whole-brain mask.
b W score based on GM volume in a temporoparietal mask.
c W score based on GM volume in a hippocampal mask.
d W score based on WMH volume (available for 796/839 cases).
e Significant difference between low and high education.
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reading activity,14 IQ,9 or a combination of these CR
measures.13 However, while these studies generally fo-
cused on clinical progression from one particular stage of
AD, we concurrently examined the longitudinal eﬀect of
CR in a broad sample of participants with NC, MCI, or AD
dementia. This approach allowed us to demonstrate the
paradoxical phenomenon of initial attenuation and sub-
sequent exacerbation within a single dataset, using a uni-
form methodology. In addition, our study design allowed
us to estimate where the CR-related inﬂection point in
clinical progression is located on the trajectory of AD. Our
results suggest that the protective role of CR continues
into the MCI stage, and that its adverse relationship with
clinical progression starts around the onset of AD de-
mentia. To our knowledge, there is one other study
demonstrating the paradoxical manifestation of CR within
one sample.10 This study was carried out in initially healthy
participants who all progressed to (AD or non-AD) de-
mentia. The authors were interested in the onset of ac-
celerated cognitive decline, which preceded the diagnosis
Figure 2 Trajectories of memory and executive functions by level of cognitive reserve
The Y-axis represents estimated marginal means. Cognitive reserve groups were created (for visualization purposes) by calculating tertiles in each disease
stage—(A) normal cognition, (B) mild cognitive impairment, and (C) Alzheimer disease (AD) dementia—based on mean gray matter (GM)–based W scores in
the temporoparietal mask. The lines displayed correspond to APOE4-positive men with a (disease stage–specific) average age and intracranial volume–
adjusted GM volume in the temporoparietal cortex. In the linearmixedmodels, W scores were included as a continuous variable, andmemory and executive
functions composite scoresweremultiplied by 100. Note that themaximum follow-up time for ADdementia participants is shorter (i.e., 24months) compared
to the other 2 groups (i.e., 120 months). ADNI = Alzheimer’s Disease Neuroimaging Initiative; ADNI-EF = standardized composite score based on a clock
drawing task, animal and vegetable category fluency, the Trail-making task, Digit Span Backwards from the Wechsler Memory Scale–Revised, and the
digit–symbol substitution task from the Wechsler Adult Intelligence Test–Revised; ADNI-MEM = standardized composite score based on the Alzheimer’s
Disease Assessment Scale–cognitive subscale word list learning task, the Rey Auditory Verbal Learning Test, Logical Memory from the Wechsler Memory
Scale–Revised, and the Mini-Mental State Examination recall task.
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Table 3 Relationship of W scores with cognitive decline in the total sample and according to disease stage
Total NC MCI AD dementia
β CI p Value β CI p Value β CI p Value β CI p Value
ADNI-MEM
Time −1.37 −1.49 to −1.24 <0.001b −0.65 −0.98 to −0.31 <0.001b −1.55 −1.71 to −1.39 <0.001b −2.45 −2.95 to −1.94 <0.001b
W score (temporoparietal)a 108.65 103.36 to 113.95 <0.001b 98.50 76.78 to 120.21 <0.001b 101.07 92.45 to 109.69 <0.001b 76.95 67.17 to 86.73 <0.001b
Time × W score (temporoparietal)a 0.45 0.25 to 0.66 <0.001b 0.48 −0.00 to 0.97 0.052 0.43 0.15 to 0.71 0.003b −0.80 −1.38 to −0.23 0.007b
ADNI-EF
Time −1.31 −1.46 to −1.17 <0.001b −0.54 −0.88 to −0.20 0.002b −1.37 −1.56 to −1.19 <0.001b −2.90 −3.63 to −2.17 <0.001b
W score (temporoparietal)a 74.23 66.21 to 82.24 <0.001b 51.15 23.61 to 78.70 <0.001b 52.14 38.75 to 65.53 <0.001b 65.72 47.81 to 83.64 <0.001b
Time × W score (temporoparietal)a 0.72 0.48 to 0.95 <0.001b 0.40 −0.10 to 0.90 0.115 0.70 0.39 to 1.01 <0.001b −0.74 −1.60 to 0.12 0.092
Abbreviations: AD =Alzheimer disease; ADNI =Alzheimer’sDiseaseNeuroimaging Initiative; ADNI-EF = standardized composite score based ona clock drawing task, animal and vegetable category fluency, the Trail-making task,
Digit Span Backwards from theWechslerMemory Scale–Revised, and the digit–symbol substitution task from theWechsler Adult Intelligence Test–Revised; ADNI-MEM= standardized composite score based on the Alzheimer’s
Disease Assessment Scale–cognitive subscale word list learning task, the Rey Auditory Verbal Learning Test, Logical Memory from the Wechsler Memory Scale–Revised, and the Mini-Mental State Examination recall task; CI =
confidence interval; GM = gray matter; NC = normal cognition; MCI = mild cognitive impairment.
Regression coefficients are unstandardized. Apart from the predictors listed above, thesemodels included age, sex, APOE4 status, andGM volume (temporoparietal), as well as its interaction with time (see table e-2, doi.org/10.
5061/dryad.cb0qk1g, for an overview of all predictors). We multiplied ADNI-MEM and ADNI-EF scores by 100 to facilitate the interpretation and presentation of the results.
a W score based on GM volume in a temporoparietal mask.
b Significant effect.
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of dementia in all participants. Results showed that higher
CR, as deﬁned by years of education, related to a shorter
time period between the onset of accelerated decline and
the dementia diagnosis. These results were interpreted as
follows: individuals with higher CR remained in phases of
gradual cognitive decline for longer (i.e., presumably
reﬂecting NC and MCI), but the transition between (late)
MCI and dementia was relatively steep. Similar to our
ﬁndings, the authors thus demonstrated that the inﬂection
from attenuation to exacerbation took place around (or
just prior to) the onset of dementia.
Strengths of this study include our neuroimaging method to
capture CR.23 W scores are not based on lifestyle proxies, but
derived from more direct measures that constitute the core of
the concept (i.e., cognition and cerebral damage). Moreover,
although CR is often conceptualized as a brain quality that an
individual has gradually developed and carried since adulthood,
our W scores only reﬂect an individual’s current degree of CR,
based on how well cerebral damage is tolerated at the present
level of cognitive function. This is important, as CR presumably
changes over time either due to alterations in lifestyle (e.g.,
decreases/increases in physical activity) or as a direct conse-
quence of disease progression. While W scores may capture
these changes, they could be missed when less dynamic CR
measures are used, such as education. That is, once education is
completed, this lifestyle proxy remains the same, regardless of
midlife and late life exposures. Another advantage of our study
is the fact that AD was established through both clinical con-
sensus and the evaluation of PET or CSF biomarkers.
Our study has several limitations. First, there was a relatively
short follow-up duration for participants with AD dementia
(median 12 months), possibly because repeated cognitive
testing is more challenging at clinically advanced stages. As
cognitive changes may be harder to capture over shorter
follow-up durations, this could have caused a bias towards the
detection of CR eﬀects in participants who were less aﬀected.
Second, the sample sizes in our stratiﬁed analyses were un-
equal, resulting in lower thresholds for signiﬁcance in MCI (n
= 437) vs AD dementia (n = 227) or NC (n = 175). In our
interpretation of the results, we therefore also considered
eﬀect sizes, which are not aﬀected by sample size. Third,
although we ensured that our entire sample was Aβ-positive,
this was based on PET imaging for some individuals, and on
CSF measures for others. While high concordance between
these 2 approaches has been demonstrated,44 other data
suggest that they cannot be used interchangeably.45,46
Fourth, as expected, our W scores were collinear with the
structural brain measures from which they were derived. On
a group level, individuals with higher W scores (i.e., greater
CR) thus had more cerebral damage. To assess the unique
association of CR with clinical progression, we therefore
adjusted the statistical models for the level of cerebral
damage at baseline. Although the assumptions for multi-
collinearity were not violated, interdependence of predictors
generally aﬀects the accuracy of the estimation of coeﬃcients
in multivariate models to at least some degree.39 However,
even despite the presumed inﬂation of CIs and standard
errors, the eﬀects for W scores still reached signiﬁcance,
which is likely related to our large sample size (i.e., >800
participants).
A more general limitation inherent to the W score method is
that its ability to capture CR is a direct consequence of the
measures included in the underlying model. If the
Table 4 Information criteria for models with W scores and other predictors of clinical progression
Model
Cox regression
Linear mixed models
ADNI-MEM ADNI-EF
AIC D AIC D AIC D
GM volume (temporoparietal)
Without W scorea 2,488.26 — 40,106.42 — 40,712.30 —
W score (temporoparietal)b 2,391.35d −96.91 39,192.15d −914.27 40,380.06d −332.24
ADAS-Cog 13
Without W scorec 2,414.98 39,093.75 40,439.19
W score (temporoparietal)b 2,391.71d −23.27 39,061.23d −32.52 40,332.57d −106.62
Abbreviations: ADAS-Cog = Alzheimer’s Disease Assessment Scale–cognitive subscale; ADNI = Alzheimer’s Disease Neuroimaging Initiative; ADNI-EF =
standardized composite score based on a clock drawing task, animal and vegetable category fluency, the Trail-making task, Digit Span Backwards from the
Wechsler Memory Scale–Revised, and the digit–symbol substitution task from the Wechsler Adult Intelligence Test–Revised; ADNI-MEM = standardized
composite score based on the Alzheimer’s Disease Assessment Scale–cognitive subscale word list learning task, the Rey Auditory Verbal Learning Test, Logical
Memory from theWechsler Memory Scale–Revised, and theMini-Mental State Examination recall task; AIC = Akaike Information Criterion; GM = graymatter.
Allmodelswere corrected for age, sex, and APOE4 status.Wemultiplied ADNI-MEMandADNI-EF scores by 100 to facilitate the interpretation andpresentation
of the results.
a This model included GM volume (temporoparietal), time, and their interaction.
b This model additionally included W score (temporoparietal) and its interaction with time.
c This model included ADAS-Cog 13, time, and their interaction.
d Lowest value (indicating better model fit).
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neuroimaging or cognitive measures do not adequately reﬂect
AD-related changes, then the resulting W scores become less
accurate. As an example, we used diﬀerent GM and WMH
volumes to quantify cerebral damage, but only 2 of them
(i.e., whole brain and temporoparietal GM volume) yielded
W scores that related to education. We argue that hippo-
campal GM-based and WMH-based W scores were less valid
measures of CR, likely because the structural measures in
these underlying models did not optimally reﬂect cerebral
damage across the AD spectrum. In fact, adjusted for
covariates, ADAS-Cog 13 showed no correlation with
WMH volume (r = 0.00, p = 0.983) in our total sample, and
while such a correlation did exist with hippocampal GM
volume (r = −0.56, p < 0.001), it was considerably lower for
participants with AD dementia (r = −0.33, p < 0.001). This
suggests that hippocampal GM volume reaches a plateau in
advanced clinical stages and thus has a more restricted dy-
namic range than whole-brain or temporoparietal GM vol-
ume. On a related note, the ADAS-Cog 13 (which was used
as a cognitive measure to calculate W scores) covers mul-
tiple cognitive domains, but executive functions are un-
derrepresented.47 Participants with executive dysfunction
may therefore have received ADAS-Cog 13 scores that
underestimated their true level of cognitive impairment.
This could have led to less accurateW scores, which could in
turn explain why the results for ADNI-EF were generally
weaker compared to ADNI-MEM. Although our neuro-
imaging measure thus contains some variance of no interest,
the nature of our results and their compatibility with the
theoretical model nevertheless suggest that the (GM-based
whole-brain and temporoparietal) W scores truly reﬂec-
ted CR.
Gaining a better understanding of how trajectories of
clinical progression diﬀer as a function of CR has both
scientiﬁc and clinical value. Our ﬁndings help to clarify
inconsistencies in the existing literature, and may further
contribute to the conceptualization of CR.1 These scientiﬁc
steps are ultimately important for the development of
nonpharmacologic strategies to delay the onset of clinical
AD by enhancing CR. Increased awareness of associations
between CR and clinical progression also has implications
for clinical trials. Matching patients based on their level of
CR may improve the ability to identify intervention eﬀects
on clinical progression. Without adequately controlling for
initial diﬀerences between treatment groups in CR, both
false-positive and -negative results can arise (i.e., an ap-
parent eﬀect of treatment that is truly related to CR, or
a true eﬀect that is masked due to CR). Moreover, CR could
act as a moderator between the intervention and clinical
outcome, such that individuals with low CR beneﬁt more
(or less) than those with high CR. Finally, taking CR into
account in a clinical setting may facilitate prognostic accuracy
for individual patients. As evidenced by the increasing interest
in biomarker-based prognostic tools for clinicians,48,49 a neu-
roimaging approach such as the W score method—especially
when CR is estimated from readily available markers (e.g.,
medial temporal lobe atrophy and MMSE scores)—could be
instrumental in this process.
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